 |
市場調查報告書
商品編碼
1518500
羥考酮藥物市場 - 按產品類型（短效、長效羥考酮）、劑型（片劑、膠囊）、適應症（神經性疼痛、癌症疼痛）、配銷通路（醫院藥房、線上藥局） - 全球預測2024 - 2032Oxycodone Drugs Market - By Product Type (Short-acting, Long-acting Oxycodone), Dosage Form (Tablets, Capsules), Indication (Neuropathic Pain, Cancer Pain), Distribution Channel (Hospital Pharmacies, Online Pharmacies) - Global Forecast 2024 - 2032 |
||||||
由於羥考酮藥物在老齡化人口疼痛管理中的作用日益增強，預計 2024 年至 2032 年，羥考酮藥物市場規模的複合年成長率將達到 5.7%。醫療保健提供者正在仔細處方這些藥物，以減輕老年患者的慢性疼痛。
隨著人口老化的擴大，人們越來越重視監測和管理鴉片類藥物的使用，以減輕依賴和濫用的風險。據世界衛生組織稱，到2050年，全球60歲及以上人口將增加一倍，達到21億。醫療專業人員正在關注替代性疼痛管理策略，例如非鴉片類藥物和療法。正在進行的研發工作也在針對老年人的具體需求創造更安全、更有效的治療方法，以確保疼痛管理獲得更好的長期結果。
整個羥考酮藥物市場分為藥物類型、劑型、適應症、配銷通路和地區。
就劑型而言，注射劑領域預計從 2024 年至 2032 年將錄得顯著的複合年成長率。醫療專業人員正在進行這些注射，以確保有效控制疼痛，尤其是在急性護理環境中。隨著慢性疼痛發病率的增加，醫療保健提供者正在最佳化羥考酮注射方案，以盡量減少副作用和依賴性風險。
從配銷通路來看，由於需要疼痛管理的患者可以輕鬆獲得多種藥物，在線藥房領域的羥考酮藥品行業預計將從 2024 年到 2032 年成長。線上平台在確保個人（尤其是行動不便的人）能夠方便地獲得藥物方面發揮著至關重要的作用。這些藥局也實施嚴格的驗證流程，以加強安全措施，防止誤用並確保正確配藥。
從地區來看，在醫療基礎設施發展和醫療支出不斷增加的推動下，亞太地區羥考酮藥物市場規模預計將在 2024 年至 2032 年間呈現強勁成長。亞太地區的政府和私營部門正在投資現代化醫療設施並擴大獲得疼痛管理治療的機會。為提高羥考酮的品質和可用性而進行的持續投資，以確保整個地區的患者獲得有效且規範的疼痛緩解，也將推動該產品的使用。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 慢性疼痛盛行率增加
- 創傷和手術事件增加
- 老年人口增加
- 藥物輸送系統的進展
- 產業陷阱與挑戰
- 監管限制
- 替代疼痛管理技術
- 成長動力
- 成長潛力分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按藥物類型，2021 - 2032
- 主要趨勢
- 短效羥考酮
- 長效羥考酮
第 6 章：市場估計與預測：按劑型，2021 - 2032
- 主要趨勢
- 平板電腦
- 膠囊
- 注射
第 7 章：市場估計與預測：按指標分類，2021 - 2032 年
- 主要趨勢
- 神經性疼痛
- 肌肉骨骼疼痛
- 癌症痛
- 術後疼痛
- 其他適應症
第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 藥局和零售藥局
- 網路藥局
第 9 章：市場估計與預測：按地區分類，2021 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Alvogen
- Ani Pharmaceutical Inc.
- Daiichi Sankyo Company Ltd.
- Endo Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Mylan N.V.
- Protega Pharmaceuticals LLC
- Purdue Pharma LP
- Quagen Pharma
- Teva Pharmaceuticals, Inc.
Oxycodone Drugs Market size is projected to record 5.7% CAGR from 2024 to 2032, driven by their growing role in pain management for the aging population. Healthcare providers are carefully prescribing these medications to alleviate chronic pain in elderly patients.
With the expansion of the aging population, there is growing emphasis on monitoring and managing opioid use to mitigate risks of dependency and misuse. According to WHO, by 2050, the world's population of people aged 60 years and older will double to 2.1 billion. Medical professionals are focusing on alternative pain management strategies, such as non-opioid medications and therapies. The ongoing R&D efforts are also creating safer and more effective treatments tailored to the specific needs of older adults for ensuring better long-term outcomes for pain management.
The overall oxycodone drugs market is segregated into drug type, dosage form, indication, distribution channel, and region.
In terms of dosage form, the injections segment is expected to record significant CAGR from 2024 to 2032. Oxycodone injections are used for managing severe pain in patients who require immediate relief. Medical professionals are administering these injections to ensure effective pain control especially in acute care settings. As the incidence of chronic pain increases, healthcare providers are optimizing oxycodone injection protocols to minimize side effects and dependency risks.
By distribution channel, the oxycodone drugs industry from the online pharmacies segment is projected to rise from 2024 to 2032, driven by the easy access to multiple drugs for patients in need of pain management. Online platforms play a crucial role in ensuring that individuals particularly those with mobility issues and can obtain their medications conveniently. These pharmacies are also implementing strict verification processes for enhancing security measures to prevent misuse and ensure proper dispensing.
Regionally, the Asia Pacific oxycodone drugs market size is projected to exhibit robust growth between 2024 and 2032, fueled by increasing healthcare infrastructure development and escalating healthcare expenditure. Governments and private sectors in APAC are investing on modernizing healthcare facilities and expanding access to pain management treatments. The ongoing investments for enhancing the quality and availability of oxycodone for ensuring that patients receive effective and regulated pain relief across the region will also push the product uptake.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increase in the prevalence of chronic pain
- 3.2.1.2 Increase in incident of trauma and surgeries
- 3.2.1.3 Rise in geriatric population
- 3.2.1.4 Advancement in drug delivery system
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Regulatory restrictions
- 3.2.2.2 Alternative pain management technologies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Short-acting oxycodone
- 5.3 Long-acting oxycodone
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Tablets
- 6.3 Capsules
- 6.4 Injections
Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Neuropathic pain
- 7.3 Musculoskeletal pain
- 7.4 Cancer pain
- 7.5 Post-operative pain
- 7.6 Other indications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Drug stores & retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Alvogen
- 10.2 Ani Pharmaceutical Inc.
- 10.3 Daiichi Sankyo Company Ltd.
- 10.4 Endo Pharmaceuticals
- 10.5 Mallinckrodt Pharmaceuticals
- 10.6 Mylan N.V.
- 10.7 Protega Pharmaceuticals LLC
- 10.8 Purdue Pharma LP
- 10.9 Quagen Pharma
- 10.10 Teva Pharmaceuticals, Inc.
